Neuman John reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director John Neuman received an equity award of 4,000 shares of common stock in the form of restricted stock units (RSUs). The award was granted at a price of $0.00 per share as compensation, not as an open-market purchase.
The RSUs will vest in full on July 1, 2027, meaning Neuman must remain eligible through that date to receive the underlying shares. Following this grant, he holds 16,200 shares of SeaStar Medical common stock in total as reported in this filing.
Van Heel Kenneth reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director Kenneth Van Heel received a grant of 4,000 restricted stock units. These RSUs vest in full on July 1, 2027, meaning he will receive the underlying shares if he remains eligible on that date. After this award, he directly holds 11,940 shares of common stock.
Baird Jennifer A reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director Jennifer A. Baird received an equity grant of 4,000 shares in the form of restricted stock units. These RSUs relate to common stock with a par value of $0.0001 per share and will vest in full on July 1, 2027.
After this award, Baird holds a total of 10,620 shares of SeaStar Medical common stock directly, reflecting her updated ownership position as reported in this Form 4 filing.
SeaStar Medical Holding Corporation approved cash and stock retention bonuses for executives Eric Schlorff and Kevin Chung under a 2026 Retention Bonus Program. Schlorff’s bonus totals $200,000 and Chung’s totals $140,000, each split into three equal installments.
Each one-third payment is scheduled for July 1, 2026, November 1, 2026, and March 1, 2027, subject to continued employment on each vesting date. Executives will also receive an additional amount equal to 25% of each payment in shares of common stock under the 2022 Omnibus Incentive Plan, based on the closing share price on each vesting date.
If an executive departs before a vesting date, remaining payments are forfeited, while a separation without cause provides a pro‑rated amount of the next payment. The company executed individual 2026 Retention Bonus Program Agreements with both executives, filed as exhibits to this report.
SeaStar Medical Holding Corporation filed an amended report describing a new separation and release agreement with Mr. Green. The agreement, entered into on June 10, 2026, provides a mutual resolution of issues surrounding a previously disputed not-for-cause termination.
Under this new agreement, SeaStar Medical has agreed to pay Mr. Green more than was disclosed in the earlier report signed on August 19, 2025. The filing indicates all claims related to that dispute are being released as part of the mutual resolution.
SeaStar Medical Holding Corporation reported results from its annual stockholder meeting held on June 17, 2026. Stockholders approved an amendment and restatement of the 2022 Omnibus Incentive Plan, increasing the number of authorized shares of common stock available under the plan from 207,046 shares to 896,546 shares, supporting future equity-based compensation.
Stockholders also elected John Neuman as a Class I director to serve until the 2029 annual meeting. They ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved a proposal allowing adjournment or postponement of the meeting if additional proxy solicitation were needed.
SeaStar Medical Holding Corporation reported a quarterly net loss of $3.5 million on $0.5 million of revenue for the three months ended March 31, 2026. Revenue rose from $0.3 million a year earlier as QUELIMMUNE pediatric therapy adoption increased, but spending on research and development ($2.3 million) and general and administrative costs ($1.7 million) kept the company unprofitable.
Cash totaled $9.3 million with total assets of $11.3 million and an accumulated deficit of $155.2 million. Management states that existing cash will not fund operations for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. SeaStar highlights ongoing commercialization of QUELIMMUNE, pivotal NEUTRALIZE-AKI and other adult trials, and notes a dismissed securities class action and a pending derivative suit.
SeaStar Medical Holding Corporation reports that, as of March 31, 2026, the reporting parties may be deemed to beneficially own 443,253 shares of Common Stock, representing 9.99% of the class based on 3,993,719 shares outstanding as of March 24, 2026. The reported position consists of four warrants held by Intracoastal exercisable for 134,615, 134,615, 131,062 and 42,961 shares, and excludes additional warrants subject to blocker provisions. Without the blocker provisions, the reporting persons may have been deemed to beneficially own 534,285 shares.
SeaStar Medical reported first quarter 2026 results showing early commercial traction but continued losses. Net revenue reached $0.5 million, up from $0.3 million a year earlier, driven by sales of its QUELIMMUNE pediatric AKI therapy and a 69% year-over-year revenue increase.
The company added seven top-rated children’s hospitals to its QUELIMMUNE customer base and advanced enrollment in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury. SeaStar recorded a net loss of $3.5 million, slightly improved from a $3.8 million loss in the prior-year quarter.
Research and development expenses were $2.3 million and general and administrative expenses were $1.7 million, both roughly flat versus last year. Cash was $9.3 million as of March 31, 2026, down from $12.0 million at year-end, reflecting ongoing operating cash use as the company invests in commercialization and its adult AKI trial.
SeaStar Medical Holding Corporation ownership disclosure: Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri each report beneficial ownership of 278,436 shares of common stock issuable upon exercise of warrants. This holding represents 6.52% of the class based on 3,993,719 shares outstanding as of March 24, 2026. The issuable shares are subject to a 9.99% beneficial ownership blocker. The reported holdings are stated as of March 31, 2026.